What Antibiotics Taught Us About Incentives

Abstract

Antibiotic resistance is usually told as a biology story, but its persistence is an economics story. A new antibiotic is most valuable to society when it is used least, which destroys the revenue model that funds drug development. This article traces how that incentive inversion emptied the antibiotic pipeline and evaluates the subscription-style reforms now being trialled.